Preparation method of platelet cytokine concentrate

Through the multi-step preparation method of platelet cytokine concentrate, the problem of insufficient platelet activation and factor release in traditional technology is solved, significantly improving the concentration and purity of growth factors, achieving more efficient tissue repair and reducing inflammatory response , has broad clinical application potential.

CN119015312AInactive Publication Date: 2024-11-26ZHEJIANG SHUNQIYI MEDICAL TECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411143019.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The activation and release of growth factors of platelets in traditional platelet-rich plasma technology are insufficient, resulting in a low concentration of extracted growth factors, limiting the therapeutic effect.

Method used

Using multi-step preparation methods for platelet cytokine concentrates, including sample collection, initial centrifugation, platelet activation and factor release, purification and concentration, quality control and storage and transportation, through low-speed centrifugation, activator addition, filtration and concentration, etc. Steps to improve platelet activation and factor release efficiency, and ensure product safety and concentration through quality testing.

Benefits of technology

It significantly improves the concentration and purity of platelet cytokines, promotes cell proliferation, angiogenesis and collagen synthesis, and has significant clinical application value, especially in the treatment of wound healing, orthopedic diseases and inflammatory diseases, reducing inflammatory response and Risk of immune rejection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015312A_ABST
    Figure CN119015312A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biomedicine, and discloses a platelet cell factor concentrate preparation method, which comprises: S1, collecting a proper amount of venous blood from a patient; s2, performing low-speed centrifugation on the collected blood; s3, centrifuging the plasma again, and further concentrating platelets; s4, adding an activating agent into the resuspended platelets to promote the platelets to release growth factors; s5, impurities are removed through filtration, and then the growth factors are purified and concentrated; s6, the extracted growth factors are detected; and S7, storing the finally prepared PCC at low temperature, and keeping a cold chain in the transportation process. The PCC contains high-concentration growth factors, and the factors can remarkably promote cell proliferation, angiogenesis and collagen synthesis and are beneficial to accelerating the wound healing process. The PCC plays an important role in soft tissue injury, postoperative healing and burn treatment, and the PCC can stimulate proliferation and differentiation of osteoblasts and cartilage cells and promote new bone formation and cartilage repair.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biomedicine, in particular to a method for preparing a platelet cytokine concentrate. Background Art

[0002] Platelets are one of the main formed elements of blood and play an important role in physiological and pathological processes such as hemostasis, wound healing, inflammatory response thrombosis and organ transplant rejection. When platelets are activated, they can release a large number of cell growth factors through the exocytosis of α particles: platelet-derived growth factor, transforming growth factor-β, insulin-like growth factor-1, vascular endothelial growth factor, etc. These cell growth factors have the function of promoting bone tissue repair and regeneration, so platelets have great application potential in the field of bone tissue engineering cartilage / bone repair.

[0003] Traditional platelet-rich plasma (PRP) technology extracts high concentrations of platelets from the patient's own blood through centrifugation to accelerate healing and regeneration. However, PRP technology has certain limitations in extraction efficiency and purity, especially some white blood cells and red blood cells may remain, leading to inflammatory reactions or reducing the therapeutic effect. In addition, in the traditional PRP method, the platelet activation and growth factor release process are not sufficient, resulting in a low concentration of extracted growth factors, which limits the therapeutic effect. The concentration and type of growth factors in PRP are limited by the number of platelets and activation efficiency, and cannot meet certain high-demand clinical applications. Summary of the invention

[0004] In view of the deficiencies in the prior art, the present invention provides a method for preparing platelet cytokine concentrates, which solves the problem that in the traditional PRP method, the platelet activation and growth factor release process are not sufficient, resulting in a low concentration of extracted growth factors and limiting the treatment effect.

[0005] To achieve the above object, the present invention is implemented by the following technical scheme: A method for preparing a platelet cytokine concentrate comprises the following steps:

[0006] S1: Sample collection

[0007] An appropriate amount of venous blood is collected from the patient using a blood collection tube containing an anticoagulant, and the sample is delivered to the laboratory under refrigerated conditions;

[0008] S2: Initial centrifugation

[0009] The collected blood is centrifuged at a low speed to separate into layers, and the plasma in the upper layer is collected;

[0010] S3: Secondary centrifugation to concentrate platelets

[0011] The plasma is centrifuged again to further concentrate the platelets, and after removing the supernatant, the platelet pellet is resuspended and prepared for subsequent processing;

[0012] S4: Platelet activation and factor release

[0013] Adding activators to the resuspended platelets and causing the platelets to release the growth factors contained within;

[0014] S5: Purification and concentration

[0015] Impurities are removed by filtration, followed by purification and concentration of the growth factors;

[0016] S6: Quality Control

[0017] Test the extracted growth factors to confirm their concentration, sterility and safety, so that the products meet the requirements for clinical use;

[0018] S7: Storage and transportation

[0019] The final prepared PCC is stored at low temperature and the cold chain is maintained during transportation.

[0020] Preferably, the sample collection method comprises the following steps:

[0021] S101: Preparation for blood collection

[0022] Equipment preparation: prepare vacuum blood collection tubes, blood collection needles, tourniquets, sterile gloves, sterile gauze, and alcohol-disinfected cotton balls. The vacuum blood collection tubes contain EDTA or citrate anticoagulants;

[0023] Environmental requirements: The blood collection environment must be kept sterile, operators must wear sterile gloves and masks, and disinfect their hands before operation;

[0024] S102: Blood collection process

[0025] Tourniquet application: Place a tourniquet on the patient’s upper arm to visualize venous filling;

[0026] Venipuncture: Use alcohol disinfectant cotton balls to disinfect the skin at the puncture site, let it stand for 20-30 seconds, then perform venous puncture, and loosen the tourniquet after bleeding;

[0027] Blood collection operation: Collect 50-100ml of blood; shake the blood gently after it flows into the blood collection tube;

[0028] Post-blood collection treatment: Pull out the blood collection needle, press the puncture point with a sterile cotton ball and let the patient keep it for 5 minutes, seal the blood collection tube, and mark the patient's information;

[0029] S103: Sample storage and transportation:

[0030] Storage: After collection, the blood sample should be immediately placed in a refrigerator at 2-8°C;

[0031] Transportation: The cold chain must be maintained throughout the transportation process, and special low-temperature transport boxes must be used. The samples must be delivered to the laboratory within 2 hours after collection.

[0032] Preferably, the method of initial centrifugation comprises the following steps:

[0033] S201: Centrifuge preparation

[0034] Equipment preparation: Calibrate the centrifuge. The centrifuge tubes are made of polypropylene, polycarbonate or high-density polyethylene;

[0035] Precooling operation: precool the centrifuge to 4-10℃ in advance;

[0036] Blood mixing: Before dispensing into centrifuge tubes, gently shake the collected whole blood sample to make the blood cells evenly distributed;

[0037] S202: Centrifugal operation

[0038] Centrifugation conditions: Set the centrifuge speed to 300-500g, the centrifugation time to 8-12 minutes, and the centrifugation temperature to 4-10°C;

[0039] Post-centrifugation treatment: After centrifugation, do not shake or sway the centrifuge tube when taking it out to avoid layer mixing;

[0040] Observation of layers: After centrifugation, blood is separated into a red blood cell layer, a buffy coat layer, and an upper layer of platelet-rich plasma;

[0041] S203: Layered operation:

[0042] Plasma collection: Use a pipette or straw to absorb the upper plasma, avoiding touching the buffy coat layer, and transfer the plasma to a new sterile centrifuge tube.

[0043] Preferably, the method for concentrating platelets by secondary centrifugation comprises the following steps:

[0044] S301: Centrifuge preparation

[0045] Centrifuge tube preparation: Use sterile centrifuge tubes to load the absorbed plasma and precool again at 4-10°C;

[0046] Centrifugation operation:

[0047] Centrifugation conditions: Set the centrifuge to 800-1200g and centrifuge for 8-15 minutes;

[0048] Treatment after centrifugation: After centrifugation, take out the centrifuge tube, the supernatant remains clear and transparent, and the bottom is the platelet precipitate;

[0049] S302: Platelet sedimentation collection:

[0050] Remove the supernatant: Use a pipette to remove the supernatant, and keep 1-2 ml of supernatant for subsequent operations;

[0051] Resuspend the precipitate: Add 1-2 ml of saline or plasma to the platelet precipitate, mix gently and resuspend the platelets.

[0052] Preferably, the method for platelet activation and factor release comprises the following steps:

[0053] S401: Activation Preparation

[0054] Activator preparation: Prepare calcium chloride or thrombin solution in advance, wherein the calcium chloride is 5%-15% and the thrombin is 10-100 units / ml;

[0055] S402: Activation operation

[0056] Adding the activator: slowly adding the activator to the suspended platelet solution, stirring gently while adding, the amount of the activator added is 0.5-3 ml activator / 10 ml platelet suspension;

[0057] Incubation: Place the mixed solution in a constant temperature incubator at 35-38°C and incubate for 10-40 minutes, stirring gently every 4-5 minutes.

[0058] Preferably, the purification and concentration method comprises the following steps:

[0059] S501: Impurity separation

[0060] Preliminary filtration: Use a 0.2-0.45 μm filter membrane to preliminarily filter the solution to remove clots and large particles formed during the activation process;

[0061] Further purification: Use a molecular weight cut-off membrane of 10-30 kDa to further concentrate and purify the growth factors and remove excess small molecule impurities;

[0062] S502: Concentration operation

[0063] Low temperature vacuum centrifugation: Place the purified growth factor solution into a vacuum centrifuge for concentration, and vacuum centrifuge at 4-10°C to reduce the volume and increase the concentration;

[0064] Concentrate to required volume: Reduce the volume of the concentrate to about 1-2 ml according to clinical application requirements;

[0065] S503: Final filtration

[0066] Final filtration: Filter the final concentrate using a 0.1-0.22 μm filter membrane to ensure the sterility of the solution and remove any particles.

[0067] Preferably, the quality control method comprises the following steps:

[0068] S601: Growth factor detection

[0069] Concentration detection: ELISA was used to detect the concentration of key growth factors, including PDGF, TGF-β and VEGF. The concentration standard of ELISA detection was:

[0070] PDGF: 5-50 ng / ml

[0071] TGF-β: 1-20 ng / ml

[0072] VEGF: 10-100 ng / ml

[0073] Purity detection: The purity of the solution is detected by SDS-PAGE or mass spectrometry analysis;

[0074] S602: Sterility Testing

[0075] Bacteria and fungi testing: Use culture medium for sterility testing and incubate to observe whether there is microbial growth. The sterility testing culture time is 7-14 days;

[0076] Endotoxin detection: The endotoxin content is detected using the LAL test, and the endotoxin limit is 0.1-0.5EU / ml;

[0077] S603: Biosafety Testing:

[0078] Activity detection: The biological activity of the solution was detected by in vitro cell proliferation experiment;

[0079] Toxicity detection: The cytotoxicity of the solution was evaluated by MTT or XTT test, wherein the cell proliferation rate of the MTT or XTT test increased by 20%-50% relative to the control group.

[0080] Preferably, the storage and transportation conditions include:

[0081] Cryopreservation conditions: The concentrated PCC preparation was rapidly frozen and stored at -20°C to -80°C to avoid repeated freezing and thawing.

[0082] Storage container: Use sterile cryotubes or cryobags to seal and store, and label with batch, date and growth factor concentration;

[0083] Cold chain transportation: Use low-temperature transport boxes with temperature monitoring to maintain a temperature of -20℃ to -80℃ throughout the process;

[0084] Thawing method: Before use, slowly thaw the PCC solution at 4-8°C;

[0085] Usage time limit: thawed PCC should be used within 24 hours and undergo a final sterility test before use.

[0086] The present invention provides a method for preparing a platelet cytokine concentrate, which has the following beneficial effects:

[0087] 1. The present invention uses PCC to contain high concentrations of growth factors, such as PDGF, TGF-β and VEGF, which can significantly promote cell proliferation, angiogenesis and collagen synthesis, and help accelerate the wound healing process. This plays an important role in soft tissue injury, postoperative healing, and burn treatment. In addition, PCC can stimulate the proliferation and differentiation of osteoblasts and chondrocytes, promote new bone formation and cartilage repair. Therefore, PCC shows significant clinical effects in the treatment of orthopedic diseases such as osteoarthritis, fractures and cartilage damage.

[0088] 2. Certain growth factors (such as TGF-β) in the PCC of the present invention have the function of regulating immune response and inhibiting inflammation. By reducing the release of inflammatory cytokines and inhibiting the action of inflammatory mediators, PCC can reduce the inflammatory response at the site of injury or surgery, thereby alleviating the pain and discomfort of the patient. And due to its anti-inflammatory properties, PCC can be used to treat chronic inflammatory diseases, such as chronic tendinitis, arthritis, etc., to help control symptoms and promote tissue repair.

[0089] 3. The PCC of the present invention is usually derived from the patient's own blood, thus greatly reducing the risk of immune rejection and allergic reactions. This makes PCC a safe and suitable treatment option for a wide range of people. And because most of the red blood cells and white blood cells are removed from PCC, the risk of potential inflammatory reactions and thrombosis is reduced, especially when injected into joints or soft tissues, which can significantly reduce the occurrence of complications.

[0090] 4. By optimizing the preparation process, the present invention can adjust the concentration and ratio of growth factors according to the specific conditions of different patients (such as age and condition), thereby achieving personalized treatment and maximizing the treatment effect. In addition, PCC can be adjusted and applied according to clinical needs, whether it is used for local injection, application during surgery, or combined with biomaterials, it can flexibly respond to different treatment scenarios. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] Figure 1 Schematic diagram of the platelet cytokine concentrate of the present invention;

[0092] Figure 2The figure is a comparison of the PCC method (bottom) of the present invention and the single centrifugation method (top) and double centrifugation method (middle) of PRP;

[0093] Figure 3 This is a schematic diagram of the clinical efficacy of PCC of the present invention on osteoarthritis (OA);

[0094] Figure 4 It is a schematic diagram of KSS (Knee Society's Knee Scoring System) scoring and VAS (Visual Analog Scale scoring system) scoring of the present invention;

[0095] Figure 5 Schematic diagram of the cell experiment of the present invention. DETAILED DESCRIPTION

[0096] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0097] Please see attached Figure 1 The present invention provides a method for preparing a platelet cytokine concentrate, comprising the following steps:

[0098] S1: Sample collection

[0099] Collect an appropriate amount of venous blood from the patient, use a blood collection tube containing an anticoagulant, and ensure that the sample is delivered to the laboratory in a timely manner under refrigerated conditions to maintain the activity and quality of the blood;

[0100] S2: Initial centrifugation

[0101] The collected blood is centrifuged at a low speed to separate into layers, and the plasma in the upper layer is carefully collected to avoid absorbing impurities in the lower layer, so as to retain the pure platelet part;

[0102] S3: Secondary centrifugation to concentrate platelets

[0103] The plasma is centrifuged again to further concentrate the platelets, and after removing the supernatant, the platelet pellet is resuspended and prepared for subsequent processing;

[0104] S4: Platelet activation and factor release

[0105] Adding an activator to the resuspended platelets and incubating at a suitable temperature for a period of time to induce the platelets to release the growth factors contained therein;

[0106] S5: Purification and concentration

[0107] Remove impurities through filtration steps and use appropriate technology to purify and concentrate the growth factors to ensure the purity and effectiveness of the final product;

[0108] S6: Quality Control

[0109] Conduct a series of tests on the extracted growth factors to confirm their concentration, sterility and safety to ensure that the products meet the requirements for clinical use;

[0110] S7: Storage and transportation

[0111] The final prepared PCC is stored at low temperature and maintained in the cold chain during transportation. It needs to be thawed under appropriate conditions before use and used as soon as possible to maintain its biological activity.

[0112] Sample collection method

[0113] S101: Preparation for blood collection

[0114] Equipment preparation: prepare vacuum blood collection tubes, blood collection needles, tourniquets, sterile gloves, sterile gauze, alcohol-disinfected cotton balls, and ensure that the blood collection tubes contain an appropriate amount of EDTA or citrate anticoagulant to prevent blood from clotting during the collection process. Blood collection equipment should be checked before use to ensure that it is not damaged and is sterile.

[0115] Environmental requirements: The blood collection environment should be kept sterile, and the blood collection table and tools should be wiped and disinfected with disinfectant before operation. Operators need to wear sterile gloves and masks and disinfect their hands before operation. It is recommended to collect blood in an operating room with high cleanliness to avoid contamination of blood samples by particles or pathogens in the air.

[0116] S102: Blood collection process

[0117] Tourniquet application: Tie a tourniquet appropriately on the patient's upper arm to make the vein filling visible. Pay attention to the tightness of the tourniquet, which should not be too tight to avoid affecting blood flow or causing discomfort to the patient.

[0118] Venipuncture: Use alcohol disinfection cotton balls to disinfect the skin at the puncture site, and let it stand for 20-30 seconds after disinfection to ensure that the alcohol evaporates before venous puncture. The puncture needle should enter the vein at a stable angle, and the tourniquet should be loosened immediately after bleeding to avoid abnormal blood flow due to excessive pressure.

[0119] Blood collection operation: Collect 50-100ml of blood and ensure that the blood flows smoothly into the blood collection tube. After the blood collection tube is filled with blood, it should be gently shaken to allow the anticoagulant and blood to be fully mixed to avoid blood coagulation. During the blood collection process, the patient's reaction should be observed to ensure that he has no discomfort symptoms.

[0120] Post-blood collection: After blood collection, remove the blood collection needle and immediately press the puncture point with a sterile cotton ball. It is recommended that the patient keep pressing for at least 5 minutes to prevent bleeding. The blood collection tube must be sealed immediately, marked with patient information and blood collection time, and the blood collection situation must be recorded for subsequent operations.

[0121] S103: Sample storage and transportation

[0122] Storage: After collection, blood samples should be immediately placed in a refrigerator at 2-8°C to keep them cool to reduce the possibility of platelet activation. The refrigerator should be used exclusively for storing blood samples to avoid mixing with other items.

[0123] Transportation: The cold chain must be maintained throughout the transportation process, and a special low-temperature transport box with temperature monitoring must be used to ensure that the temperature of the sample is maintained at 2-8°C during transportation. The sample should be delivered to the laboratory within 2 hours after collection to avoid the quality of the sample being reduced due to a long period of time. An appropriate amount of ice packs should be placed in the transport box, but the sample should not be in direct contact with the ice pack to prevent freezing of the blood.

[0124] Method of primary centrifugation

[0125] S201: Centrifuge preparation

[0126] Equipment preparation: Calibrate the centrifuge to ensure it is in good working condition. Centrifuge tubes should be made of polypropylene, polycarbonate or high-density polyethylene, which are not only sterile and resistant to low temperatures, but also can avoid breakage or chemical reactions during centrifugation.

[0127] Precooling operation: Precool the centrifuge to 4-10℃ in advance. The centrifuge tube should also be precooled in a low temperature environment to ensure that the entire centrifugation process is carried out under low temperature conditions, thereby reducing the risk of platelet activation.

[0128] Blood mixing: Before dispensing into centrifuge tubes, gently shake the collected whole blood sample to evenly distribute the blood cells to avoid poor separation due to uneven distribution. Be careful when operating and avoid shaking violently or too much.

[0129] S202: Centrifugal operation

[0130] Centrifugation conditions: Set the centrifuge speed to 300-500g, the centrifugation time to 8-12 minutes, and the centrifugation temperature to 4-10°C. These conditions ensure the best blood stratification effect while maintaining the integrity of the platelets.

[0131] Post-centrifugation processing: After centrifugation, the centrifuge tube should be kept horizontal when it is taken out, without vibration or shaking to avoid layer mixing. The centrifuge tube should be placed on a sterile operating table and the stratification should be carefully observed.

[0132] Observation of stratification: After centrifugation, blood is usually stratified into a red blood cell layer at the bottom, a buffy coat layer in the middle, and a platelet-rich plasma layer at the top. Obvious and clear stratification, with no obvious mixing between the layers, indicates a good centrifugation effect.

[0133] S203: Layered Operation

[0134] Plasma collection: Use a pipette or straw to carefully draw the upper plasma, avoiding touching the buffy coat layer to reduce leukocyte contamination. Transfer the collected plasma to a new sterile centrifuge tube, ensuring that the operation is performed in a sterile environment to prevent exogenous contamination.

[0135] Method for concentrating platelets by secondary centrifugation

[0136] S301: Centrifuge preparation

[0137] Centrifuge tube preparation: Use sterile centrifuge tubes to load the absorbed plasma and precool it again in a 4-10°C environment to ensure that the temperature remains low throughout the entire processing process to maintain the activity and function of platelets.

[0138] S302: Centrifugal operation

[0139] Centrifugation conditions: Set the centrifuge speed to 800-1200g and the centrifugation time to 8-15 minutes. Centrifugation under these conditions can effectively concentrate platelets without causing excessive mechanical stress to them, ensuring the retention of platelet function.

[0140] Treatment after centrifugation: After centrifugation, take out the centrifuge tube. The supernatant should remain clear and transparent. If turbidity or granular precipitation appears, the operation process needs to be rechecked. The platelet precipitation is at the bottom and the color should be light yellow.

[0141] S303: Platelet sedimentation collection

[0142] Remove the supernatant: Use a pipette to remove the supernatant, being careful not to disturb the platelet sediment at the bottom. Keep 1-2 ml of the supernatant to facilitate resuspension in subsequent operations.

[0143] Resuspend the pellet: Add 1-2 ml of saline or plasma to the platelet pellet, mix gently and resuspend the platelets to ensure that the pellet is completely dissolved to form a uniform suspension in preparation for the subsequent activation step.

[0144] Methods of platelet activation and factor release

[0145] S401: Activation Preparation

[0146] Activator preparation: Prepare calcium chloride or thrombin solution in advance. The concentration of calcium chloride should be between 5% and 15%, and the concentration of thrombin should be between 10 and 100 units / ml. All solutions should be prepared under sterile conditions and ensure their freshness and activity before use.

[0147] S402: Activation operation

[0148] Addition of activator: Slowly add the activator to the suspended platelet solution, stirring gently while adding to ensure that the activator is evenly distributed. The amount of activator added is 0.5-3ml / 10ml platelet suspension. Avoid adding too quickly or too violently to prevent bubbles or platelet damage.

[0149] Incubation: Place the mixed solution in a 35-38°C incubator and incubate for 10-40 minutes to ensure that the platelets are fully activated and release growth factors. During the incubation period, gently stir the solution every 5 minutes to ensure uniform activation and release. The length of the incubation time should be adjusted appropriately according to the specific experimental needs to achieve the best results.

[0150] Purification and concentration methods

[0151] S501: Impurity separation

[0152] Preliminary filtration: Use a filter membrane with a pore size of 0.2-0.45μm to preliminarily filter the solution to remove clots and large particles formed during the activation process. Filtration should be performed under sterile conditions to ensure that impurities are completely removed and do not contaminate the final product.

[0153] Further purification: Select a molecular weight cutoff membrane with a molecular weight range of 10-30 kDa to further concentrate and purify the growth factor and remove excess small molecule impurities, free proteins or metabolites. The molecular weight cutoff range of the selected membrane should be optimized according to the size and properties of the target factor.

[0154] S502: Concentration operation

[0155] Low temperature vacuum centrifugation: Place the purified growth factor solution in a vacuum centrifuge for concentration, and control the temperature at 4-10°C. Use vacuum centrifugation to reduce the volume of the solution and increase the factor concentration. Vacuum centrifugation should be performed at a low speed to avoid excessive heat accumulation that may lead to growth factor degradation.

[0156] Concentrate to the required volume: According to clinical application requirements, reduce the volume of the concentrate to about 1-2 ml. The liquid volume should be monitored at any time during the concentration process, and the centrifugation time and vacuum pressure should be adjusted according to the degree of concentration.

[0157] S503: Final filtration

[0158] Final filtration: Filter the final concentrate using a filter membrane with a pore size of 0.1-0.22μm to ensure the sterility of the solution and remove any particles. The filtered product should be free of obvious suspended particles and impurities, transparent and uniform in color. After filtration, subsequent processing or storage should be carried out immediately to avoid long-term exposure to non-sterile environments.

[0159] Quality Control Methods

[0160] S601: Growth factor detection

[0161] Concentration test: Use ELISA to test the concentration of key growth factors, PDGF, TGF-β and VEGF. The test results should be in line with the preset concentration range (PDGF: 5-50ng / ml, TGF-β: 1-20ng / ml, VEGF: 10-100ng / ml). The concentration test results of each batch of products should be recorded as a basis for quality tracking.

[0162] Purity test: The purity of the solution is tested by SDS-PAGE or mass spectrometry to ensure that there are no excessive impurity proteins. The purity test results should show the main band of the target protein, and other bands should be as few as possible or absent.

[0163] S602: Sterility Testing

[0164] Bacteria and fungi testing: Use culture medium for sterility testing, incubate for 7-14 days, and observe whether there is microbial growth. Sterility testing should include negative and positive controls to ensure the accuracy and reliability of the results.

[0165] Endotoxin detection: Use LAL test to detect endotoxin content, and the endotoxin limit should be controlled between 0.1-0.5EU / ml. Endotoxin test results should meet safety standards, otherwise purification or production should be carried out again.

[0166] S603: Biosafety Testing

[0167] Activity test: The biological activity of the solution is tested by in vitro cell proliferation test. The MTT or XTT test should show that the cell proliferation rate increases by 20%-50% compared with the control group to prove the effectiveness of the product.

[0168] Toxicity test: Perform MTT or XTT test to evaluate the cytotoxicity of the solution to ensure that the solution has no toxic effect on cells within the effective concentration range. The test results should show that the cell activity is not lower than the control group standard.

[0169] Storage and transportation conditions

[0170] Cryopreservation conditions

[0171] Storage temperature: The concentrated PCC preparation should be quickly frozen and stored at -20°C to -80°C to avoid repeated freezing and thawing to prevent the loss of growth factor activity. During the freezing process, the product should be packaged in multiple tubes to facilitate subsequent use and reduce the number of thawing times.

[0172] Save Container

[0173] Container selection: Use sterile cryotubes or cryobags for sealed storage, and choose low-temperature resistant and non-absorbent materials. Cryocontainers should be labeled with the batch, date, growth factor concentration, and operator name for traceability.

[0174] Cold Chain Transport

[0175] Transportation conditions: Use a low-temperature transport box with temperature monitoring to maintain a temperature of -20°C to -80°C throughout the entire process. During transportation, temperature fluctuations should be controlled within ±2°C to ensure product stability. The refrigerant in the transport box should be adjusted appropriately according to the transportation time and external ambient temperature to maintain a constant low temperature.

[0176] Thawing method

[0177] Thawing procedure: Before use, slowly thaw the PCC solution at 4-8°C, and avoid rapid thawing in a high temperature environment to prevent growth factor degradation or inactivation. The thawed PCC should be temporarily stored in an environment of 2-8°C, and avoid long-term exposure to room temperature.

[0178] Time limit

[0179] Usage time control: thawed PCC should be used within 24 hours and undergo final sterility testing before use. Unused portions after thawing should be discarded to avoid secondary freezing and use to prevent quality problems.

[0180] The following is a detailed description of the materials and nouns in the steps:

[0181] Material

[0182] Vacuum blood collection tube:

[0183] Definition: A vacuum blood collection tube is a sealed container used to collect venous blood. It has a preset negative pressure inside and can automatically draw in a certain volume of blood. The blood collection tube usually contains an anticoagulant to prevent blood clotting.

[0184] Purpose: Used to collect blood samples while ensuring that the samples will not spill or be contaminated during transportation and storage.

[0185] EDTA (ethylenediaminetetraacetic acid):

[0186] Definition: EDTA is a widely used anticoagulant that prevents blood clotting by chelating calcium ions in the blood.

[0187] Uses: During the blood collection process, EDTA is used to keep the blood sample in a liquid state for subsequent processing and analysis.

[0188] Citric Acid (Citrate):

[0189] Definition: Citrate is also a common anticoagulant, usually in the form of sodium citrate. It blocks the clotting process by binding to calcium ions.

[0190] Uses: Used for blood collection, especially when it is necessary to preserve the activity of certain components in the blood, such as platelets and coagulation factors.

[0191] Polypropylene (PP):

[0192] Definition: Polypropylene is a plastic material with excellent chemical and heat resistance, widely used in laboratory consumables, including centrifuge tubes and test tubes.

[0193] Application: Due to its good tolerance, polypropylene centrifuge tubes are often used for centrifugation and cryopreservation of blood or biological samples.

[0194] Polycarbonate (PC):

[0195] Definition: Polycarbonate is a clear, tough plastic with high impact resistance and good optical clarity.

[0196] Application: Polycarbonate centrifuge tubes are often used in high-speed centrifugation and experiments that require observation of the internal state of the sample, but they have poor tolerance to certain chemicals.

[0197] High-density polyethylene (HDPE):

[0198] Definition: HDPE is a plastic with high chemical resistance and low-temperature toughness, commonly used to manufacture various types of containers and pipes.

[0199] Application: HDPE centrifuge tubes are suitable for low-temperature storage and centrifugal operation, and are often used in experiments that require long-term storage of samples.

[0200] Calcium Chloride (CaCl2):

[0201] Definition: Calcium chloride is an inorganic salt commonly used as an activator to induce platelets to release internally stored growth factors.

[0202] Uses: During the preparation of PCC, calcium chloride is used to activate platelets, prompting them to release growth factors for tissue repair.

[0203] Thrombin:

[0204] Definition: Thrombin is an enzyme that promotes blood clotting by converting fibrinogen into fibrin.

[0205] Uses: During platelet activation, thrombin is used to rapidly induce the release of growth factors from platelets while also forming a gel to help immobilize these factors.

[0206] Molecular weight cut-off membrane:

[0207] Definition: Molecular weight cut-off membrane is a small filter membrane that selectively passes molecules and can separate and concentrate specific biomolecules based on their size.

[0208] Uses: During the purification process, it is used to concentrate and purify growth factors of a specific size and remove small molecule impurities.

[0209] ELISA (Enzyme-linked immunosorbent assay):

[0210] Definition: ELISA is an immunological technique widely used to detect and quantify proteins, antigens, and antibodies. It achieves quantitative detection through antigen-antibody reaction combined with enzyme markers.

[0211] Purpose: To detect the concentration of growth factors in PCC, such as PDGF, TGF-β and VEGF, to ensure that the preparation achieves the expected effect.

[0212] SDS-PAGE (Sodium dodecyl sulfate-polyacrylamide gel electrophoresis):

[0213] Definition: SDS-PAGE is an electrophoresis technique that uses sodium dodecyl sulfate as a denaturant to separate protein molecules and detect them according to their molecular weight.

[0214] Purpose: To analyze the protein purity in PCC to ensure that there is no excessive impurity protein.

[0215] LAL test (Limulus Amebocyte Lysate Test):

[0216] Definition: The LAL test is a biochemical test used to detect endotoxins (bacterial endotoxins) in biological products.

[0217] Use: Used to detect the endotoxin content in PCC to ensure that it is within a safe range and to avoid inducing fever or other immune responses in clinical applications.

[0218] MTT / XTT assay:

[0219] Definition: The MTT and XTT assays are in vitro assays for assessing cell proliferation and viability based on an enzymatic reaction that converts a pale yellow tetrazolium salt into a dark formazan dye.

[0220] Use: To evaluate the effect of PCC on cell proliferation to ensure that it has sufficient biological activity in the application, and to evaluate its toxicity to ensure its safety to cells.

[0221] Glossary:

[0222] Platelet Cytokine Concentrate (PCC):

[0223] Definition: PCC is a biological preparation extracted and concentrated from platelets that contains a variety of growth factors that can promote tissue repair and regeneration.

[0224] Uses: Widely used in the treatment of cartilage damage, osteoarthritis, trauma repair and other medical fields to promote tissue healing and regeneration through local application.

[0225] Platelet-Rich Plasma (PRP):

[0226] Definition: PRP is a type of plasma separated from a patient's own blood that contains high concentrations of platelets and a variety of growth factors.

[0227] Uses: Used to promote the repair of soft tissue and bone tissue, widely used in beauty, plastic surgery, sports medicine and other fields.

[0228] Red blood cell layer, buffy coat layer, plasma layer:

[0229] Definition: In the stratification of blood after centrifugation, the red blood cell layer is the bottom sedimentation layer, containing dense red blood cells; the buffy coat is a thin layer located between red blood cells and plasma, mainly composed of white blood cells and platelets; the plasma layer is the upper transparent liquid part, mainly containing water, protein, nutrients and a small amount of platelets.

[0230] Use: During the PCC preparation process, these layers are processed and separated separately to obtain platelet-rich plasma for further preparation.

[0231] Endotoxin:

[0232] Definition: Endotoxins are part of the cell wall of Gram-negative bacteria that are released into the body when these bacteria die or lyse and can trigger severe immune responses such as fever, hypotension, and shock.

[0233] Application: In the production of biological products, the detection and removal of endotoxins are very important steps to ensure the safety of products and the health of patients.

[0234] These materials and terms play a vital role in the PCC preparation process, ensuring the smooth progress of the entire process and the high quality of the final product. Understanding the role of these materials and terms will help you better master and apply related technologies in practice.

[0235] PCC(PlateletCytokinesConcentrates)

[0236] It is superior to all existing platelet preparation technologies and has great potential for clinical application:

[0237] Able to obtain extremely high concentrations of cytokines

[0238] Can minimize the contamination of white blood cells and red blood cells,

[0239] Avoid adverse reactions caused by plasma.

[0240] PCC Features:

[0241] Through flow cytometry detection, it can be seen that the use of tissue regeneration and repair technology can effectively reduce the contamination and interference of foreign cells, so that the platelet positive rate of the prepared product is as high as more than 99%, which is significantly better than the single centrifugation method and the double centrifugation method of PRP. Figure 2 shown.

[0242] Above: PRP single centrifugation method

[0243] Positive rate: 68.25%

[0244] Average fluorescence intensity: 59.79

[0245] Middle table: PRP secondary centrifugation method

[0246] Positive rate: 90.95%

[0247] Average fluorescence intensity: 162.14

[0248] Table below: PCC method

[0249] Positive rate: 99.11%

[0250] Average fluorescence intensity: 770.75.

[0251] Clinical efficacy of PCC on osteoarthritis (OA):

[0252] A clinical trial report of 118 patients showed that ( Figure 3 - Figure 4), after 3 to 6 months of treatment with tissue regeneration and repair technology, the symptoms of osteoarthritis (OA) patients were significantly relieved, the KSS score and VAS score were significantly improved, and the effect was better than conventional treatment (control) methods.

[0253] KSS(KneeSociety'sKneeScoringSystem)

[0254] VAS(VisualAnalogScalescoringsystem)

[0255] Cell experiments showed that Figure 5 ), using tissue regeneration and repair technology can significantly promote the proliferation activity of chondrocytes, and the effect increases with increasing concentration.

[0256] Since PCC is autologous, it fundamentally avoids the concerns that exogenous growth factors may cause immune rejection, spread diseases, and that xenogeneic recombinant gene products may change the human genetic structure. It has good safety and significant efficacy.

[0257] PCC application prospects:

[0258] The adverse reactions of PCC knee joint injection are mainly mild knee joint swelling and pain after injection, which mostly last for several minutes to several hours and resolve on their own within a few days after treatment. No serious complications such as bleeding, fever, hematoma, lower limb venous thrombosis, systemic adverse reactions, etc. have occurred.

[0259] Osteoarthritis (OA) is the most common degenerative bone metabolic disease in clinic and one of the most common geriatric diseases. It is related to factors such as aging trauma and is the main cause of disability in adults. PCC can promote the repair and regeneration of OA cartilage degeneration, inhibit the progression of OA and improve the joint activity function of patients. It has great application potential in the treatment of OA.

[0260] Table 1 Functions of growth factors released by platelets

[0261]

[0262] Fibronectin (fibronectin affects the shaping of the extracellular matrix and promotes cell adhesion)

[0263] Osteocalcin (osteocalcin binds to hydroxyapatite to promote bone mineralization; promotes the proliferation of osteoblasts and chondrocytes) Vitronectin promotes adhesion between cells and extracellular matrix; enhances fibrin aggregation; participates in immune response and thrombosis; promotes the formation of new blood vessels

[0268] Osteonectin (osteonectin connects collagen and apatite to promote matrix mineralization; promotes matrix remodeling and maintains bone mass) Stromal cell-derived factor-inhibits the migration of bone marrow to endothelial stem cells; mediates cell growth, migration and transcriptional activation 1α (SDF-1α) Platelet activation releases a variety of growth factors that can promote the regeneration and growth of surrounding cells, promote cartilage regeneration and repair, and accelerate local wound healing. It is fast, simple, safe and has no side effects. Therefore, platelets have great application potential in the field of bone tissue engineering cartilage / bone repair.

[0272] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for preparing a platelet cytokine concentrate, characterized in that: The following steps are involved: S1: Sample collection An appropriate amount of venous blood is collected from the patient using a blood collection tube containing an anticoagulant, and the sample is delivered to the laboratory under refrigerated conditions; S2: Initial centrifugation The collected blood is centrifuged at a low speed to separate into layers, and the plasma in the upper layer is collected; S3: Secondary centrifugation to concentrate platelets The plasma is centrifuged again to further concentrate the platelets, and after removing the supernatant, the platelet pellet is resuspended and prepared for subsequent processing; S4: Platelet activation and factor release Adding activators to the resuspended platelets and causing the platelets to release the growth factors contained within; S5: Purification and concentration Impurities are removed by filtration, followed by purification and concentration of the growth factors; S6: Quality Control Test the extracted growth factors to confirm their concentration, sterility and safety, so that the products meet the requirements for clinical use; S7: Storage and transportation The final prepared PCC is stored at low temperature and the cold chain is maintained during transportation.

2. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The sample collection method comprises the following steps: S101: Preparation for blood collection Equipment preparation: prepare vacuum blood collection tubes, blood collection needles, tourniquets, sterile gloves, sterile gauze, and alcohol-disinfected cotton balls. The vacuum blood collection tubes contain EDTA or citrate anticoagulants; Environmental requirements: The blood collection environment must be kept sterile, operators must wear sterile gloves and masks, and disinfect their hands before operation; S102: Blood collection process Tourniquet application: Place a tourniquet on the patient’s upper arm to visualize venous filling; Venipuncture: Use alcohol disinfectant cotton balls to disinfect the skin at the puncture site, let it stand for 20-30 seconds, then perform venous puncture, and loosen the tourniquet after bleeding; Blood collection operation: Collect 50-100ml of blood; shake the blood gently after it flows into the blood collection tube; Post-blood collection treatment: Pull out the blood collection needle, press the puncture point with a sterile cotton ball and let the patient keep it for 5 minutes, seal the blood collection tube, and mark the patient's information; S103: Sample storage and transportation: Storage: After collection, the blood sample should be immediately placed in a refrigerator at 2-8°C; Transportation: The cold chain must be maintained throughout the transportation process, and special low-temperature transport boxes must be used. The samples must be delivered to the laboratory within 2 hours after collection.

3. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The method of initial centrifugation comprises the following steps: S201: Centrifuge preparation Equipment preparation: Calibrate the centrifuge. The centrifuge tubes are made of polypropylene, polycarbonate or high-density polyethylene; Precooling operation: precool the centrifuge to 4-10℃ in advance; Blood mixing: Before dispensing into centrifuge tubes, gently shake the collected whole blood sample to make the blood cells evenly distributed; S202: Centrifugal operation Centrifugation conditions: Set the centrifuge speed to 300-500g, the centrifugation time to 8-12 minutes, and the centrifugation temperature to 4-10°C; Post-centrifugation treatment: After centrifugation, do not shake or sway the centrifuge tube when taking it out to avoid layer mixing; Observation of layers: After centrifugation, blood is separated into a red blood cell layer, a buffy coat layer, and an upper layer of platelet-rich plasma; S203: Layered operation: Plasma collection: Use a pipette or straw to absorb the upper plasma, avoiding touching the buffy coat layer, and transfer the plasma to a new sterile centrifuge tube.

4. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The method for concentrating platelets by secondary centrifugation comprises the following steps: S301: Centrifuge preparation Centrifuge tube preparation: Use sterile centrifuge tubes to load the absorbed plasma and precool again at 4-10°C; Centrifugation operation: Centrifugation conditions: Set the centrifuge to 800-1200g and centrifuge for 8-15 minutes; Treatment after centrifugation: After centrifugation, take out the centrifuge tube, the supernatant remains clear and transparent, and the bottom is the platelet precipitate; S302: Platelet sedimentation collection: Remove the supernatant: Use a pipette to remove the supernatant, and keep 1-2 ml of supernatant for subsequent operations; Resuspend the precipitate: Add 1-2 ml of saline or plasma to the platelet precipitate, mix gently and resuspend the platelets.

5. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The method for platelet activation and factor release comprises the following steps: S401: Activation Preparation Activator preparation: Prepare calcium chloride or thrombin solution in advance, wherein the calcium chloride is 5%-15% and the thrombin is 10-100 units / ml; S402: Activation operation Adding the activator: slowly adding the activator to the suspended platelet solution, stirring gently while adding, the amount of the activator added is 0.5-3 ml activator / 10 ml platelet suspension; Incubation: Place the mixed solution in a constant temperature incubator at 35-38°C and incubate for 10-40 minutes, stirring gently every 4-5 minutes.

6. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The purification and concentration method comprises the following steps: S501: Impurity separation Preliminary filtration: Use a 0.2-0.45 μm filter membrane to preliminarily filter the solution to remove clots and large particles formed during the activation process; Further purification: Use a molecular weight cut-off membrane of 10-30 kDa to further concentrate and purify the growth factors and remove excess small molecule impurities; S502: Concentration operation Low temperature vacuum centrifugation: Place the purified growth factor solution into a vacuum centrifuge for concentration, and vacuum centrifuge at 4-10°C to reduce the volume and increase the concentration; Concentrate to required volume: Reduce the volume of concentrate to about 1-2 ml according to clinical application requirements; S503: Final filtration Final filtration: Filter the final concentrate using a 0.1-0.22 μm filter membrane to ensure the sterility of the solution and remove any particles.

7. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The quality control method comprises the following steps: S601: Growth factor detection Concentration detection: ELISA was used to detect the concentration of key growth factors, including PDGF, TGF-β and VEGF. The concentration standard of ELISA detection was: PDGF: 5-50 ng / ml TGF-β: 1-20 ng / ml VEGF: 10-100 ng / ml Purity detection: The purity of the solution is detected by SDS-PAGE or mass spectrometry analysis; S602: Sterility Testing Bacteria and fungi testing: Use culture medium for sterility testing and incubate to observe whether there is microbial growth. The sterility testing culture time is 7-14 days; Endotoxin detection: The endotoxin content is detected using the LAL test, and the endotoxin limit is 0.1-0.5EU / ml; S603: Biosafety Testing: Activity detection: The biological activity of the solution was detected by in vitro cell proliferation experiment; Toxicity detection: The cytotoxicity of the solution was evaluated by MTT or XTT test, wherein the cell proliferation rate of the MTT or XTT test increased by 20%-50% relative to the control group.

8. The method for preparing a platelet cytokine concentrate according to claim 1, characterized in that: The storage and transportation conditions include: Cryopreservation conditions: The concentrated PCC preparation was rapidly frozen and stored at -20°C to -80°C to avoid repeated freezing and thawing. Storage container: Use sterile cryotubes or cryobags to seal and store, and label with batch, date and growth factor concentration; Cold chain transportation: Use low-temperature transport boxes with temperature monitoring to maintain a temperature of -20℃ to -80℃ throughout the process; Thawing method: Before use, slowly thaw the PCC solution at 4-8°C; Usage time limit: thawed PCC should be used within 24 hours and undergo a final sterility test before use.

Citation Information

Patent Citations

  • Application of highly concentrated growth factor

    CN108096053A

  • Preparation method of autologous venous blood cell activator

    CN114099544A

  • Method of preparing a growth factor concentrate derived from human platelets

    US20150224173A1